SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease

Title:SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease

Volume: 18 Issue: 15

Author(s): Dong Han, Jinda Wang, Sai Ma, Yundai Chen and Feng Cao*

Affiliation:

• Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853,China

Keywords: SIRT1, ischemia reperfusion injury, metabolic disease, heart, resveratrol, therapy, target.

Abstract: Background: Cardiovascular diseases, especially ischemic heart disease and cardiometabolic disease, remain to be the leading cause of morbidity and mortality worldwide. Despite recent progress in diagnostic and therapeutic approaches, the incidence of cardiovascular disease is still rising. Therefore, alternative favorable treatment is urgently needed to rescue the fast growing numbers of patients.

Objective: Herein we aimed to review the relevant role and explore the possibility of SIRT1 as a promising target for protection of heart from ischemia/reperfusion injury and cardiometabolic diseases.

Results: The activation of SIRT1 participates in a variety of important metabolic and physiologic processes including stress resistance, metabolism, apoptosis and energy balance in heart ischemia injury and cardiometabolic disease.

Conclusion: Current medication targeting SIRT1 may represent a new therapeutic trend for the prevention of cardiovascular disease that is related to energy balance and metabolism.

Cite this article as:

Han Dong, Wang Jinda, Ma Sai, Chen Yundai and Cao Feng*, SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450116666150630110529